KLF4 mediates the contradictory effects of phenylethyl isothiocyanate in gastric cancer intervention
- PMID: 40504295
- DOI: 10.1007/s12032-025-02795-1
KLF4 mediates the contradictory effects of phenylethyl isothiocyanate in gastric cancer intervention
Abstract
Phenethyl isothiocyanate (PEITC) exerts anti-gastric cancer effect, however, the molecular mechanism has not yet been elucidated. KLF4 is an important regulatory molecule in gastric cancer. The programmed death ligand 1 (PD-L1) interacts with programmed cell death 1 (PD-1), inhibits function of cytotoxic T-lymphocyte and helps gastric cancer cells evade immune surveillance. The present study aimed to investigate the effect of PEITC against gastric cancer and the roles of KLF4 and PD-L1 in the anti-gastric cancer effect of PEITC. The effects of PEITC on gastric cancer cell proliferation and apoptosis were detected by EdU assay, flow cytometric analysis, immunoblotting and in vivo xenograft tumor experiment. The expression of KLF4 and PD-L1 was examined in PEITC-treated gastric cancer cells using immunoblotting, immunofluorescence and flow cytometric analysis. Co-culture system was used to assess the cancer cell-killing effect of PEITC combined with anti-PD-L1 blockade in gastric cancer. The results showed that PEITC suppressed cell activities both in vitro and in vivo. PEITC upregulated the expression of KLF4, which suppressed cyclin D1 expression and activated Bax expression, and mediated the growth inhibition effect of PEITC in gastric cancer. Meanwhile, we found that KLF4 induced by PEITC transcriptionally activated PD-L1 expression and diminished anti-cancer effects of anti-PD-L1 therapy in gastric cancer cells. Findings from this research revealed that PEITC restricted gastric cancer cell growth through activating KLF4. PEITC attenuated anti-PD-L1 therapy efficacy attributing to KLF4-upregulated PD-L1. These results uncover a novel mechanism of PEITC in gastric cancer intervention.
Keywords: Gastric cancer; KLF4; PD-L1; Phenethyl isothiocyanate.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare that they have no competing interests. Ethical approval: The procedures were approved by the Committee on the Ethics of Animal Experiments of Nanjing University of Chinese Medicine (202306A076). Consent for publication: Not applicable.
Similar articles
-
Ultrasound nanobubble-based combinational strategies of loaded miR-107-3p and CD133 Ab for anti-PD-L1 and anti-hepatocellular cancer stem cells.Int J Pharm. 2025 Feb 10;670:125140. doi: 10.1016/j.ijpharm.2024.125140. Epub 2025 Jan 3. Int J Pharm. 2025. PMID: 39756595
-
METTL3 Inhibition Restores PD-L1 Expression and CD8+ T-cell Cytotoxic Function in Immunotherapy-Treated Gastric Cancer.Cancer Immunol Res. 2025 Jul 2;13(7):1037-1052. doi: 10.1158/2326-6066.CIR-24-1179. Cancer Immunol Res. 2025. PMID: 40299705
-
Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.J Cancer Res Clin Oncol. 2021 Mar;147(3):691-701. doi: 10.1007/s00432-020-03446-w. Epub 2021 Jan 2. J Cancer Res Clin Oncol. 2021. PMID: 33389078 Free PMC article.
-
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.Diagn Pathol. 2018 Feb 9;13(1):12. doi: 10.1186/s13000-018-0689-9. Diagn Pathol. 2018. PMID: 29426340 Free PMC article.
-
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.Clin Transl Oncol. 2024 Oct;26(10):2488-2502. doi: 10.1007/s12094-024-03442-3. Epub 2024 Apr 16. Clin Transl Oncol. 2024. PMID: 38625495
References
-
- Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286–287:18–24. - PubMed
-
- Hara M, Hanaoka T, Kobayashi M, Otani T, Adachi HY, Montani A, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Matsuzawa T, Ikekawa T, Sasaki S, Tsugane S. Cruciferous vegetables, mushrooms, and gastrointestinal cancer risks in a multicenter, hospital-based case-control study in Japan. Nutr Cancer. 2003;46(2):138–47. - PubMed
-
- Voorrips LE, Goldbohm RA, van Poppel G, Sturmans F, Hermus RJ, van den Brandt PA. Vegetable and fruit consumption and risks of colon and rectal cancer in a prospective cohort study: The Netherlands cohort study on diet and cancer. Am J Epidemiol. 2000;152(11):1081–92. - PubMed
-
- Gao S, Wang W, Li J, Wang Y, Shan Y, Tan H. Unveiling polysaccharides of Houttuynia cordata Thunb.: extraction, purification, structure, bioactivities, and structure-activity relationships. Phytomedicine. 2025;138:156436. - PubMed
MeSH terms
Substances
Grants and funding
- YKK23137/Health Science Development Foundation of Nanjing, China
- 23-25-2R21/Youth Talent Training Program of the Affiliated Nanjing Brain Hospital, Nanjing Medical University
- 81803217/National Natural Science Foundation of China
- 035091005007/Jiangsu Province "The 14th Five-year Plan" Key Discipline-Public Health and Preventive Medicine
LinkOut - more resources
Full Text Sources
Medical
Research Materials